Chris Hollis is Professor of Child & Adolescent Psychiatry at the University of Nottingham and Consultant in Developmental Neuropsychiatry with Nottinghamshire Healthcare NHS Trust. Before moving to Nottingham, Chris trained in psychiatry at the Maudsley Hospital and Institute of Psychiatry, where he completed his PhD. In addition to his role as Clinical Director of the NIHR Healthcare Technology Co-operative (HTC) in mental health and neurodevelopmental disorders (MindTech), Chris is Director of the Centre for ADHD and Neurodevelopmental Disorders Across the Lifespan (CANDAL) and leads the NIHR CLAHRC NDL Children and Young People's research theme. His areas of research interest include ADHD, Tourette syndrome, early onset schizophrenia and the development and implementation of digital technologies to enhance assessment and monitoring of mental health disorders. Over the last 5 years Chris has a research income of over £2.5 million. Chris was a member of the RAE 2008 panel for psychiatry, clinical psychology and neuroscience. He has served on numerous academic advisory and funding bodies including the MRC and Mental Health Foundation. Chris is lead clinician for the Developmental Neuropsychiatry Service at QMC, with special interests in lifespan neurodevelopmental disorders including ADHD, Tourette's, ASD, child and adolescent-onset psychoses and psychopharmacology. Since 2007, Chris has developed and led the Adult ADHD Clinic at QMC. Chris was a member of the NICE Guideline Development Group (GDG) for ADHD (2005-8), NICE ADHD Quality Standard Advisory Committee (2012-13) and chaired the NICE GDG for schizophrenia and psychosis in children and young people (2011-13).
Chris Hollis appraises a recent Cochrane systematic review, which casts doubt over the quality of trial evidence and the clinical effectiveness of Methylphenidate for ADHD.[read the full story...]